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http:WHAT THIS PAPER ADDS
A meta-analysis was performed of randomized placebo controlled trials on bone marrow -derived cell therapy in
critical limb ischemia. This is an update of the meta-analysis by Teraa et al., published in Annals of Surgery in
2013. Since the publication of that article, the results of ﬁve additional placebo controlled trials involving 276
patients have been published. The 2013 meta-analysis found an advantage of cell therapy, with a divergent
effect between the placebo controlled and non-placebo controlled trials. In the current analysis of only placebo
controlled trials, no improvement with cell therapy was observed in amputation rates, survival, or amputation
free survival.Objective/Background: Critical limb ischemia (CLI) is the most advanced stage of peripheral artery disease (PAD),
and many patients with CLI are not eligible for conventional revascularization. In the last decade, cell based
therapies have been explored as an alternative treatment option for CLI. A meta-analysis was conducted of
randomized placebo controlled trials investigating bone marrow (BM) derived cell therapy in patients with CLI.
Methods: The MEDLINE, Embase, and the Cochrane Controlled Trials Register databases were systematically
searched, and all included studies were critically appraised by two independent reviewers. The meta-analysis was
performed using a random effects model.
Results: Ten studies, totaling 499 patients, were included in this meta-analysis. No signiﬁcant differences were
observed in major amputation rates (relative risk [RR] 0.91; 95% conﬁdence interval [CI] 0.65e1.27), survival (RR
1.00; 95% CI 0.95e1.06), and amputation free survival (RR 1.03; 95% CI 0.86e1.23) between the cell treated and
placebo treated patients. The ankle brachial index (mean difference 0.11; 95% CI 0.07e0.16), transcutaneous
oxygen measurements (mean difference 11.88; 95% CI 2.73e21.02), and pain score (mean difference e0.72; 95%
CI e1.37 to e0.07) were signiﬁcantly better in the treatment group than in the placebo group.
Conclusions: This meta-analysis of placebo controlled trials showed no advantage of stem cell therapy on the
primary outcome measures of amputation, survival, and amputation free survival in patients with CLI. The
potential beneﬁt of more sophisticated cell based strategies should be explored in future randomized placebo
controlled trials.
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Critical limb ischemia (CLI) is at the end of the peripheral
artery disease (PAD) spectrum and associated with high
amputation and mortality rates and poor quality of life.1e3
In the last decade, cell based therapies have been explored
as a treatment option for patients with CLI with no option
for surgical or endovascular revascularization. Since 2002,
several studies have suggested beneﬁcial effects of cell
based therapies.4e6 However, the initial pioneering studies
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blinded, which made them susceptible to bias and thus
prevented deﬁnite conclusions about treatment effects.
Results of larger and placebo controlled trials have
become available during the last few years. The results of
the studies published until 2012 were previously
reviewed and summarized,7 with the conclusion that
bone marrow (BM)-derived cell therapy was a promising
strategy in CLI. Importantly, the effects of the placebo
controlled and non-placebo controlled trials showed
divergence, with no beneﬁt on amputation rates if only
placebo controlled trials were analyzed. However,
because only ﬁve placebo controlled trials were available
at that time, this result could have been caused by the
lack of statistical power.
Since 2012, the results of ﬁve additional randomized
placebo controlled trials have been published.8e12 These
additional studies provide a signiﬁcant increase in the
number of patients treated with cell based therapy in well-
designed placebo controlled trials and may provide stron-
ger evidence and new guidance on the clinical applicability
and effect of BM derived cell therapy in CLI. Therefore, a
meta-analysis was performed that included only the ran-
domized placebo controlled trials on BM derived cell
therapy in CLI.METHODS
Search strategy
On 15 April 2015, MEDLINE, Embase, and the Cochrane
Controlled Trial Register were searched using identical
search criteria to those used by Teraa et al. (see Appendix
1)7 to identify new trials published since the initial search
on 24 February 2012. Inclusion and exclusion criteria were
deﬁned before the literature search, as listed in Table 1.
Studies using the contralateral limb as an internal control
were included if treatment was randomized. The articles
were independently screened for eligibility by two re-
viewers (S.P.W. and M.T.). Disagreements were resolved by
consensus.Table 1. Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Study type: RCT Animals
Therapy: BM derived
cell therapy
Children or neonates
Comparator: placebo Review or case report (n < 10)
Outcome: major amputation,
survival, ABI, TcO2, pain score
No CLI or diabetic foot
Language not English, Dutch,
or German
Gene or growth factor therapy
Diagnostic, prognostic, or
etiologic studies
Note. RCT ¼ randomized controlled trial; BM ¼ bone marrow;
ABI ¼ ankle brachial index; TcO2, transcutaneous oxygen;
CLI ¼ critical limb ischemia.Critical appraisal, data extraction, and management
Quality assessment and critical appraisal of the newly
included trials was also performed by the two reviewers
independently, according to a modiﬁed version of the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines.13 Also performed were an additional risk of bias
analysis and analysis by the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) system,
which rates quality of evidence and grading strength of
recommendations in systematic reviews.14
Primary outcomes were major amputation, survival, and
amputation free survival (AFS). Secondary outcomes were
ankle brachial index (ABI), transcutaneous oxygen (TcO2)
measurements, pain score, and ulcer healing. Data from the
last follow up available were used for the analyses. Pain
scores were converted to a scale ranging from 0 (no pain) to
4 (severe pain), and changes in pain score (D pain score)
were analyzed. If raw data were unavailable, but only
graphs or ﬁgures, GetData Graph Digitizer 2.25 software (S.
Fedorov)15 was used to extract the data. If SEMs were re-
ported instead of SDs, SDs were calculated assuming that
the data were distributed parametrically. If medians and
interquartile ranges were reported, means and SDs were
estimated using methods described previously.16Statistical analysis
All statistical analyses in this meta-analysis were performed
using Review Manager 5.1 software (The Cochrane Collab-
oration, Copenhagen, Denmark). A random effects model
was applied to calculate treatment effects because statis-
tical and methodological heterogeneity was assumed. The
weighted mean difference or relative risk (RR) and the
respective 95% conﬁdence intervals (CI) were calculated to
express the treatment effects. Heterogeneity between the
studies included in the analyses was determined using the
chi-square test. Inconsistency was quantiﬁed with the I2
statistic, where I2 values < 25% represent mild inconsis-
tency, values between 25% and 50% represent moderate
inconsistency, and values > 50% suggest severe heteroge-
neity between the studies. Statistical signiﬁcance was
assumed at p < .05.
Sensitivity analyses were performed by repeating the
main computations using a ﬁxed effects model and by
repeating the main computations without the studies that
used the contralateral leg as a control, because it was not
ruled out that stem cells, owing to a systemic effect, could
inﬂuence the results in the control leg. Sensitivity analyses
were also performed for studies including > 50 patients and
studies investigating intramuscular versus intra-arterial
administration. Funnel plots were visually inspected for
small study effects or publication bias.
RESULTS
Search results and study characteristics
The same search strategy used since the initial search in
2012 found new articles that met the search criteria after
Figure 1. Flow chart of study selection (ﬁrst search in 2012 plus
second search in 2015).
Cell Therapy in Critical Limb Ischemia 777duplications were deleted. After the titles and abstracts
were screened based on the inclusion and exclusion criteria,
14 full text articles were assessed, and, ultimately, data
from ﬁve articles, including 276 patients, were eligible for
further analysis. These articles were added to the placebo
controlled studies from the previous meta-analysis,7 which
resulted in 10 articles eligible for inclusion (Fig. 1). The
reasons for the exclusion of 18 articles are summarized in
Fig. 1.5,6,17e32
The articles were assessed for quality and risk of bias, and
these results are summarized in Table 2 and Supplementary
Fig. 1. There was no disagreement between the reviewers
on any of the topics. Characteristics of the studies are
summarized in Table 3. In addition, a GRADE evidenceTable 2. Critical appraisal.
Study Randomizationa Allocation concealment
Benoit et al.3 þ þ
Li et al.8 e e
Lu et al.35 þ e
Gupta et al.9 þ þ
Losordo et al.12 þ e
Powell et al.34 þ þ
Raval et al.10 e þ
Tateishi-Yuyama et al.4 þ þ
Teraa et al.11 þ þ
Walter et al.33 e e
Note. a (þ) ¼ clearly deﬁned; () ¼ inadequate/not reported. b (þ) ¼
(þ/) ¼ 5e10%; () > 10%. d (þ) ¼ All; () ¼ crossover.proﬁle was reconstructed and is summarized in
Supplementary Table 1.
The results represent data from 499 patients who were
enrolled in the 10 included randomized controlled trials
(RCTs). The median number of patients per study was 40.5
(range 10.0e160.0). Of the included patients, 240 were
treated with cell therapy, 196 patients were treated with
placebo, and 63 were treated with cell therapy in one leg
and placebo in the other. The mean age and the percentage
of patients with Fontaine grade IV and diabetes were similar
between the treatment and control groups. The mean
follow up of the studies was 7.5 months, with one study
reporting 3 months or less of follow up and only three
studies with a follow up of more than 6 months (Table 3).
The cell type injected and the administration route varied
between the studies. Two studies used intra-arterial
administration,11,33 and the remaining studies applied the
cells intramuscularly. Five of 10 studies used BM derived
mononuclear cells (BMMNC),3,4,8,11,33 one used BM derived
mesenchymal stem cells (BMMSC),9 one RCT used
Ixmyelocel-T, a commercial pre-expanded cell product ob-
tained from BM,34 one study used CD34þ cells,12 and one
used CD133þ cells.10 One study had a three-armed trial
design with a BMMNC, a BMMSC, and a placebo group.35
Patients with bilateral CLI were randomized to BMMNC or
BMMSC in one leg and placebo in the other; hence, the
contralateral leg served as an internal control. The original
publication used the placebo treated limbs of both groups
as a merged control group, without separated data for the
BMMNC group and the BMMSC group. Therefore, the study
groups were stratiﬁed in a BMMSC group, a BMMNC group,
and the control group containing the contralateral limbs of
both groups. This resulted in double -counting of the pla-
cebo treated patients, as described previously by Teraa
et al.7
Major amputation, survival, and AFS
From nine studies reporting amputation rates, amputation
occurred in 56 of 277 limbs treated with cell therapy and in
58 of 270 limbs in the control groups. Cell therapy did not
signiﬁcantly reduce major amputation rates overall
compared with placebo (RR 0.91; 95% CI 0.65e1.27;
Fig. 2A). If studies using the contralateral leg as a controla Blindingb Loss to follow upc Treated in assigned groupd
þ þ þ
þ/ þ þ
þ e þ
þ þ þ
þ þ/ þ
þ þ þ
þ þ e
þ e þ
þ þ þ
þ þ þ
double blind; (þ/) ¼ single blind; () ¼ not blinded. c (þ) < 5%;
Table 3. Characteristics of included articles.
Study na Therapy Control Administration
route
Follow up Mean
age (y)a
Fontaine
IV (%)a
Diabetes
(%)
Benoit et al.3 34/14 BMMNC Placebo IM 6 mo 72.5/65.7 68/50 53/43
Li et al.8 29/29 BMMNC Placebo IM 6 mo 63.0/61.0 59/64 41/45
Lu et al.35 21/41 limbs BMMNC Placebo IM 24 wk 63.0  8.0 100/100 100/100
Lu et al.35 20/41 limbs BMMSC Placebo IM 24 wk 65.0  10.0 100/100 100/100
Gupta et al.9 10/10 BMMSC Placebo IM 6 mo 46.7/43.0 70/80 NA
Losordo et al.12 16/12 CD34þ Placebo IM 12 mo 67.1/66.2 58/44 63/42
Powell et al.34 48/24 Ixmyelocel-T Placebo IM 12 mo 69.2/67.3 60/67 44/63
Raval et al.10 3/7 CD133þ Placebo IM 12 mo 65.0/85.0 29/33 43/33
Tateishi-Yuyama et al.4 22/22 limbs BMMNC Placebo IM 24 wk 69.0  11.0 70 65
Teraa et al.11 81/79 BMMNC Placebo IA 6 mo 69.0/65.0 63/63 36/39
Walter et al.33 19/21 BMMNC Placebo IA 3 mo 64.4/64.5 79/71 53/48
Note. NA ¼ not available; IM ¼ intramuscular; IA ¼ intra-arterial; SC ¼ subcutaneous; BMMNC ¼ bone marrow derived mononuclear
cells; BMMSC ¼ bone marrow derived mesenchymal stem cells; ACP ¼ angiogenic cell precursors; M-PBMC ¼ mobilized peripheral
blood mononuclear cells.
a Cell treated group/placebo group.
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survival was similar between the treatment and placebo
groups (RR 1.00; 95% CI 0.95e1.06). AFS was reported or
could be retrieved in eight studies and did not signiﬁcantly
differ between the treatment and control group, with a RR
of 1.03 (95% CI 0.86e1.23; Fig. 2B).
Ulcer healing
Six studies evaluated complete ulcer healing in 253 limbs.
No signiﬁcant beneﬁt of BM derived cell therapy was
observed compared with control (RR 1.40; 95% CI 0.99e
1.97; Fig. 2C), especially when studies using the contralat-
eral limb as control were excluded (RR 1.09; 95% CI 0.68e
1.76).
ABI and TcO2
The ABI at the end of follow up in six studies was compared
and was signiﬁcantly higher in the therapeutic group than in
the control group (mean difference 0.11; 95% CI 0.07e0.16
[p < .01]; Fig. 2D). When studies without a separate control
group were excluded, the mean difference in ABI was
slightly smaller (0.10; 95% CI 0.04e0.16). Four studies re-
ported that TcO2 was also signiﬁcantly higher in the group
treated with BM derived cell therapy compared with the
control group, with a mean difference of 11.88 (95% CI
2.73e21.02; p ¼ .01), as shown in Fig. 2E. When studies
with the contralateral leg as the control were excluded, the
mean difference was less pronounced (3.69; 95% CI 2.62e
4.76). Importantly, the chi-square test showed considerable
heterogeneity between the studies for ABI and TcO2.
Pain score
Decreases in pain scores were signiﬁcantly greater in the
cell treated group than in the control group. The mean
decrease in pain score was 1.3 in the treatment group and
0.6 in the placebo group. The mean difference in the
decrease between the treatment and placebo groups wase0.72 (95% CI e1.37 to e0.07; p ¼ .03), as shown in
Fig. 2F. Analysis of only studies with a separate control
population showed a mean difference of e0.44 (95% CI e
1.35 to 0.46).Safety issues
Results from the included articles showed that BM derived
cell therapy appeared to be relatively safe. Observed
adverse effects were mostly mild and transient. The most
frequently reported adverse effects were pain and
tenderness at the BM aspiration site. Other reported
treatment related adverse events and effects were a
transient and well tolerated hematocrit decrease in the
treatment group compared with the control group,3 two
patients each with groin hematoma,11,33 or malig-
nancies,3,33 and one patient each with stent thrombosis,33
pseudoaneurysm,33 moderate hypotension,12 or worsening
of CLI after the injection.12Sensitivity analyses
The sensitivity analyses based on ﬁxed effects models did
not substantially change the observed effects, and only the
difference in ulcer healing became statistically signiﬁcant
(random effects model: RR 1.40; 95% CI 0.99e1.97; ﬁxed
effects model: RR 1.49; 95% CI 1.15e1.93). Sensitivity
analysis based on studies including > 50 patients did not
substantially change the observed effects, except for ulcer
healing (all studies included: RR 1.40; 95% CI 0.99e1.79;
studies including > 50 patients: RR 1.71; 95% CI 1.32e
2.21). When trials using intramuscular or intra-arterial
administration were compared, a smaller effect size for
intra-arterial administration was observed; however, the
differences were not signiﬁcant. This may have been owing
to the small number of trials (two studies) investigating the
intra-arterial route.11,33 The funnel plots were not indicative
of small study effects or publication bias, based on visual
inspections.
Figure 2. Meta-analysis of endpoints in placebo controlled bone marrow (BM) derived cell therapy trials. Note. CI ¼ conﬁdence interval;
BMMNC ¼ BM derived mononuclear cells; BMMSC ¼ BM derived mesenchymal stem cells; AFS ¼ amputation free survival; ABI ¼ ankle
brachial index; TcO2 ¼ transcutaneous oxygen.
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The present meta-analysis of 10 randomized placebo
controlled trials investigating BM derived cell therapy in 499
patients with CLI showed no differences in amputation rates,
survival, or AFS between cell treated and placebo treated
patients. Although ABI, TcO2, and pain scores appeared to be
better in the groups treated with BM derived cells, the
percentage of healed ulcers was not signiﬁcantly different
between the groups. Notably, BM derived cell therapy
seemed to be a relatively safe treatment option because the
adverse events were mostly mild and transient.
Previous meta-analyses of trials of cell therapy that were
and were not placebo controlled showed promising ampu-
tation rates, survival, and AFS. In particular, the ﬁrst non-
placebo controlled and relatively small studies showed ad-
vantages of cell therapy, but the larger studies and placebo
controlled trials showed less convincing results on hard end
points such as amputation, survival, and AFS. The present
analysis included ﬁve additional placebo controlled trials
comprising 276 additional patients and did not show sig-
niﬁcant effects of BM derived cell therapy on the primary
outcome measures. Because improvement occurred in the
treatment arm and in the placebo arm in several tri-
als,3,9,11,12,33 an adequate double blinded design is of great
importance.
ABI and TcO2 seemed better in the cell therapy group;
however, analyses showed large heterogeneity based on
chi-square tests, and therefore these results are less reli-
able. Moreover, the value of an increased ABI or TcO2 level
is questionable if amputation rates, survival, and ulcer
healing do not improve.
The current meta-analysis mainly included studies that
investigated the intramuscular administration of BM
derived cells,3,4,8e10,12,34,35 and most investigators used
BMMNC.3,4,8,11,33,35 The limited numbers of trials and pa-
tients precluded decent subgroup analyses for the different
administration routes or cell types.
That circulating BM derived progenitor cells are
dysfunctional and that levels are lower in patients with CLI
than in healthy controls because of prolonged pro-
inﬂammatory stimuli has been suggested.36 This might
explain the absence of treatment effect seen in this meta-
analysis. However, Gremmels et al. suggested that this
disease mediated cell dysfunction in patients with CLI is
reversed in BMMSCs,37 making them possibly more effec-
tive in neovascularization therapy for CLI. In addition,
BMMSCs might provide additional beneﬁt when used in an
allogeneic approach, for example off the shelf availability
and circumvention of BM aspiration procedures in the frail
patient with CLI.38
Although a clear difference between trials that used
intra-arterial and intramuscular administration was not
observed, evidence shows that BM derived cells mainly act
via paracrine pathways. One advantage of intramuscular
administration could be the creation of “local depots” of
stem cells with increased local paracrine activity and localrelease of arteriogenic cytokines.18,39 This suggests that
intramuscular administration might be better and should be
explored in future clinical trials.
This meta-analysis has some limitations. The number of
published trials is relatively small, and the included studies
had a small sample size. Most of the studies were pilot
studies3,4,8e10,12,34,35 and did not include a sample size
calculation or were designed for safety analysis. Hence,
most studies were not powered to prove therapeutic
efﬁcacy.
Only four of the 10 studies randomized > 50 patients,
and just one included > 100 patients, which could lead to
small study bias. The GRADE analysis of the included studies
generally showed low study quality for all outcomes (see
Supplementary Material).
Follow up time was generally limited, and none of the
included trials had a follow up > 12 months. The interval
between the start of inclusion and publication of the trial
result was relatively long for most trials, which can cause
heterogeneity in the included patient population, for
example because of changes in secondary prevention. There
is no generally accepted unequivocal deﬁnition of the “no
option” patient with CLI. Patient ineligibility for revascu-
larization is often determined in multidisciplinary consensus
meetings; therefore, differences among and within trials
can arise in which patients are included in a trial, which
could inﬂuence outcomes in different studies.
In conclusion, this meta-analysis of 10 placebo controlled
trials of BM derived cell therapy in 499 patients with CLI
showed no advantage of cell therapy on the primary
outcome measures of amputation, survival, and AFS. This
meta-analysis underlines the need for future well designed
double blinded and placebo controlled randomized trials
that are adequately powered, to investigate speciﬁc BM
derived cell therapeutic strategies. From the available evi-
dence it is believed that future cell therapy in CLI should
focus on speciﬁc cellular therapies. It has recently been
seen that the neovascularization capacity of mesenchymal
stem cells is not compromised in patients with CLI, sug-
gesting that autologous mesenchymal stem cells may be
suitable for cellular therapy in patients with CLI.16 A joint
international effort would be advisable to assure that a
future trial would be adequately powered and ﬁnished
within an acceptable timeframe.
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Syntax “Medline”
(“Peripheral arterial disease”[TIAB] OR PAD[TIAB] OR
“peripheral arterial occlusive disease”[TIAB] OR PAOD[TIAB]
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mia”[TIAB] OR CLI[TIAB] OR “Severe limb ischemia”[TIAB]
OR “Severe limb ischaemia”[TIAB] OR “arteriosclerosis
obliterans”[TIAB] OR “thromboangitis obliterans”[TIAB] OR
Buerger[TIAB] OR “Fontaine 3”[TIAB] OR “Fontaine 4”[TIAB]
OR “Fontaine III”[TIAB] OR “Fontaine IV”[TIAB] OR “Ruth-
erford 4”[TIAB] OR “Rutherford 5”[TIAB] OR “Rutherford
6”[TIAB] OR Amputation[TIAB] OR “Ischemic ulcer*”[TIAB]
OR “Ischaemic ulcer*”[TIAB] OR gangrene[TIAB] OR necrosis
[TIAB] OR “diabetic foot”[TIAB] OR “diabetic ulcer”[TIAB])
AND (BM[TIAB] OR “Bone marrow” [TIAB] OR BM-MNC
[TIAB] OR BMMNC[TIAB] OR BMMC[TIAB] OR “Bone
marrow mononuclear cell*”[TIAB] OR “bone marrow
derived mononuclear cell”[TIAB] OR PB-MNC[TIAB] OR
PBMNC[TIAB] OR PB-MC[TIAB] OR PBMC[TIAB] OR “Pe-
ripheral blood mononuclear cell*”[TIAB] OR “peripheral
blood derived mononuclear cell*”[TIAB] OR “Stem cell*”[-
TIAB] OR “Progenitor cell*”[TIAB] OR cell[TIAB] OR cellular
[TIAB] OR “Cell based” [TIAB] OR “Cell based” [TIAB] OR
“Neovascular*”[TIAB] OR angiogen*[TIAB] OR “Mesen-
chymal stem cell*”[TIAB] OR “Mesenchymal stromal
cell*”[TIAB] OR MSC[TIAB]) AND (therapy[TIAB] OR thera-
pies[TIAB] OR therapeutic*[TIAB] OR intervention[TIAB] OR
infusion[TIAB] OR administration[TIAB] OR injection[TIAB]
OR application[TIAB] OR treatment[TIAB] OR trans-
plantation[TIAB]) AND (RCT[TIAB] OR randomis*[TIAB] OR
randomiz*[TIAB] OR trial[TIAB] OR “placebo con-
trolled”[TIAB] OR placebo controlled[TIAB] OR placebo
[TIAB] OR “clinical trial”[TIAB] OR “prospective study”[TIAB]
OR “double-blind”[TIAB] OR “double blind”[TIAB] OR blin-
ded[TIAB])
Syntax “Embase”
(“Peripheral arterial disease”:ti,ab OR PAD:ti,ab OR “pe-
ripheral arterial occlusive disease”:ti,ab OR PAOD:ti,ab OR
“Critical limb ischemia”:ti,ab OR “Critical limb ischaemia”:-
ti,ab OR CLI:ti,ab OR “Severe limb ischemia”:ti,ab OR “Severe
limb ischaemia”:ti,ab OR “arteriosclerosis obliterans”:ti,ab
OR “thromboangitis obliterans”:ti,ab OR Buerger:ti,ab OR
“Fontaine 3”:ti,ab OR “Fontaine 4”:ti,ab OR “Fontaine III”:-
ti,ab OR “Fontaine IV”:ti,ab OR “Rutherford 4”:ti,ab OR
“Rutherford 5”:ti,ab OR “Rutherford 6”:ti,ab OR Amputa-
tion:ti,ab OR “Ischemic (ulcer OR ulcers)”:ti,ab OR “Ischaemic
(ulcer OR ulcers)”:ti,ab OR gangrene:ti,ab OR necrosis:ti,ab
OR “diabetic foot”:ti,ab OR “diabetic (ulcer OR ulcers)”:ti,ab)
AND (BM:ti,ab OR “Bonemarrow”:ti,ab OR BM-MNC:ti,ab OR
BMMNC:ti,ab OR BMMC:ti,ab OR “Bone marrow mono-
nuclear (cell OR cells)”:ti,ab OR “bone marrow derived
mononuclear cell”:ti,abORPB-MNC:ti,abORPBMNC:ti,abOR
PB-MC:ti,ab OR PBMC:ti,ab OR “Peripheral blood mono-
nuclear (cell OR cells)”:ti,ab OR “peripheral blood derived
mononuclear (cell OR cells)”:ti,ab OR “Stem (cell OR cell-
s)”:ti,ab OR “Progenitor (cell OR cells)”:ti,ab OR cell:ti,ab OR
cellular:ti,ab OR “Cell based”:ti,ab OR “Cell based”:ti,ab OR
Neovascular*:ti,ab OR angiogen*:ti,ab OR “Mesenchymal
stem (cell OR cells)”:ti,ab OR “Mesenchymal stromal (cell OR
cells)”:ti,ab OR MSC:ti,ab) AND (therapy:ti,ab OR ther-
apies:ti,ab OR therapeutic*:ti,ab OR intervention:ti,ab OR
infusion:ti,ab OR administration:ti,ab OR injection:ti,ab ORapplication:ti,ab OR treatment:ti,ab OR transplantation:ti,ab)
AND (RCT:ti,ab OR randomis*:ti,ab OR randomiz*:ti,ab OR
trial:ti,ab OR “placebo controlled”:ti,ab OR placebo con-
trolled:ti,ab OR placebo:ti,ab OR “clinical trial”:ti,ab OR
“prospective study”:ti,ab OR “double-blind”:ti,ab OR “double
blind”:ti,ab OR blinded:ti,ab)
Syntax “Cochrane”
(“Peripheral arterial disease” OR PAD OR “peripheral
arterial occlusive disease” OR PAOD OR “Critical limb
ischemia” OR “Critical limb ischaemia” OR CLI OR “Severe
limb ischemia” OR “Severe limb ischaemia” OR “arterio-
sclerosis obliterans” OR “thromboangitis obliterans” OR
Buerger OR “Fontaine 3” OR “Fontaine 4” OR “Fontaine III”
OR “Fontaine IV” OR “Rutherford 4” OR “Rutherford 5” OR
“Rutherford 6” OR Amputation OR “Ischemic ulcer*” OR
“Ischaemic ulcer*” OR gangrene OR necrosis OR “diabetic
foot” OR “diabetic ulcer*”) AND (BM OR “Bone marrow” OR
BM-MNC OR BMMNC OR BMMC OR “Bone marrow
mononuclear cell*” OR “bone marrow derived mononuclear
cell” OR PB-MNC OR PBMNC OR PB-MC OR PBMC OR
“Peripheral blood mononuclear cell*” OR “peripheral blood
derived mononuclear cell*” OR “Stem cell*” OR “Progenitor
cell*” OR cell OR cellular OR “Cell based” OR “Cell based”
OR “Neovascular*” OR angiogen* OR “Mesenchymal stem
cell*” OR “Mesenchymal stromal cell*” OR MSC) AND
(therapy OR therapies OR therapeutic* OR intervention OR
infusion OR administration OR injection OR application OR
treatment OR transplantation) AND (RCT OR randomis* OR
randomiz* OR trial OR “placebo controlled” OR placebo
controlled OR placebo OR “clinical trial” OR “prospective
study” OR “double-blind” OR “double blind” OR blinded)APPENDIX A. SUPPLEMENTARY MATERIAL
Supplementary material related to this article can be found
at http://dx.doi.org/10.1016/j.ejvs.2015.08.018REFERENCES
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